Nexthera Capital’s Stemline Therapeutics STML Stock Holding History
Bought
Maintained
Sold
Other funds holding STML
Nexthera Capital's STML Position: Q2 2019 in Review
Nexthera Capital sold out of Stemline Therapeutics (STML) in Q2 2019, closing a stake of 325,526 shares — an estimated $4.18M sold.
Nexthera Capital first reported a position in STML in Q1 2018 and held it in 5 quarters. The position peaked at $9.7M in Q3 2018. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.
- Nexthera Capital reported no remaining Stemline Therapeutics position as of Q2 2019 after selling out during the quarter.
- Nexthera Capital sold 325,526 Stemline Therapeutics shares in Q2 2019, an estimated $4.18M.
- Nexthera Capital first reported a position in Stemline Therapeutics in Q1 2018 and held it in 5 quarters.
- Nexthera Capital's Stemline Therapeutics position peaked at $9.7M in Q3 2018.
- 96 funds tracked by Wall St. Rank held Stemline Therapeutics as of Q2 2019.
Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.